National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Department of Metabolism and Endocrinology, the Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China.
National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Department of Metabolism and Endocrinology, the Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China; Health Law Research Center, School of Law, Central South University, Changsha, China.
Biochem Pharmacol. 2024 Apr;222:116104. doi: 10.1016/j.bcp.2024.116104. Epub 2024 Feb 29.
Adipose tissues (AT) are an important endocrine organ that secretes various functional adipokines, peptides, non-coding RNAs, and acts on AT themselves or other distant tissues or organs through autocrine, paracrine, or endocrine manners. An accumulating body of evidence has suggested that many adipokines play an important role in liver metabolism. Besides the traditional adipokines such as adiponectin and leptin, many novel adipokines have recently been identified to have regulatory effects on the liver. Additionally, AT can produce extracellular vesicles (EVs) that act on peripheral tissues. However, under pathological conditions, such as obesity and diabetes, dysregulation of adipokines is associated with functional changes in AT, which may cause liver diseases. In this review, we focus on the newly discovered adipokines and EVs secreted by AT and highlight their actions on the liver under the context of obesity, nonalcoholic fatty liver diseases (NAFLD), and some other liver diseases. Clarifying the action of adipokines and adipose tissue-derived EVs on the liver would help to identify novel therapeutic targets or biomarkers for metabolic diseases.
脂肪组织 (AT) 是一个重要的内分泌器官,它分泌各种功能性脂肪因子、肽、非编码 RNA,并通过自分泌、旁分泌或内分泌方式作用于 AT 本身或其他远处的组织或器官。越来越多的证据表明,许多脂肪因子在肝脏代谢中发挥着重要作用。除了传统的脂肪因子如脂联素和瘦素外,最近还发现了许多新型脂肪因子对肝脏具有调节作用。此外,AT 可以产生细胞外囊泡 (EVs),这些 EVs 作用于外周组织。然而,在肥胖和糖尿病等病理条件下,脂肪因子的失调与 AT 的功能变化有关,这可能导致肝脏疾病。在这篇综述中,我们重点介绍了 AT 分泌的新发现的脂肪因子和 EVs,并强调了它们在肥胖、非酒精性脂肪性肝病 (NAFLD) 和其他一些肝脏疾病背景下对肝脏的作用。阐明脂肪因子和脂肪组织衍生的 EVs 对肝脏的作用将有助于确定代谢性疾病的新治疗靶点或生物标志物。